Evidence map›Paper›PMID 35702159›Full record

ArticlemedRxiv : the preprint server for health sciences2022

α2,6-Sialylation is Upregulated in Severe COVID-19 Implicating the Complement Cascade.

Rui Qin, Emma Kurz, Shuhui Chen, Briana Zeck, Luis Chiribogas, Dana Jackson, Alex Herchen, Tyson Attia, Michael Carlock, Amy Rapkiewicz and 4 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Rui QinDepartment of Chemistry, University of Alberta, Edmonton, Alberta, Canada.
Emma KurzDepartment of Cell Biology, NYU Grossman School of Medicine, 550 1st Avenue, New York, New York, USA.
Shuhui ChenDepartment of Chemistry, Biomedical Research Institute, New York University, New York, New York, USA.
Briana ZeckCenter for Biospecimen Research and Development, NYU Langone, New York, New York, USA.
Luis ChiribogasCenter for Biospecimen Research and Development, NYU Langone, New York, New York, USA.
Dana JacksonUniversity of Alberta Hospital, Edmonton, Alberta, Canada.
Alex HerchenUniversity of Alberta Hospital, Edmonton, Alberta, Canada.
Tyson AttiaUniversity of Alberta Hospital, Edmonton, Alberta, Canada.
Michael CarlockCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.
Amy RapkiewiczDepartment of Pathology, NYU Long Island School of Medicine, Mineola, NY, USA.
Dafna Bar-SagiDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, New York, USA.
Bruce RitchieUniversity of Alberta Hospital, Edmonton, Alberta, Canada.
Ted M RossCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.
Lara K MahalDepartment of Chemistry, University of Alberta, Edmonton, Alberta, Canada.
Alberta Hospital Edmonton · CANew York University · USUniversity of Alberta · CAUniversity of Georgia · USBiomedical Research Institute · USLong Island University · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Richard Lewis Possemato · 1985 to 2026
$83.1M
COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
NCI NIH HHS P30 CA016087NIAID NIH HHS 75N93019C00052
6 · The paper itself

Abstract

Better understanding of the mechanisms of COVID-19 severity is desperately needed in current times. Although hyper-inflammation drives severe COVID-19, precise mechanisms triggering this cascade and what role glycosylation might play therein is unknown. Here we report the first high-throughput glycomic analysis of COVID-19 plasma samples and autopsy tissues. We find α2,6-sialylation is upregulated in plasma of patients with severe COVID-19 and in the lung. This glycan motif is enriched on members of the complement cascade, which show higher levels of sialylation in severe COVID-19. In the lung tissue, we observe increased complement deposition, associated with elevated α2,6-sialylation levels, corresponding to elevated markers of poor prognosis (IL-6) and fibrotic response. We also observe upregulation of the α2,6-sialylation enzyme ST6GAL1 in patients who succumbed to COVID-19. Our work identifies a heretofore undescribed relationship between sialylation and complement in severe COVID-19, potentially informing future therapeutic development.

Identifiers

PMID35702159
PMCPMC9196116
OpenAlexW4281922377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.